CYT997 is an orally available vascular targeting and cytotoxic agent that has proven effective in animal models of a wide range of tumour types including breast, prostate and colon, as...
- Mechanism
- Curator reviewed
CYT997 is a vascular disrupting agent and a tubulin inhibitor for various cancers. The essential role of microtubules in cell division and the capacity of drugs that interact with the protein subunits of microtubules (α- and β-tubulin) to interfere with the cell cycle, have made tubulin a highly successful target for the development of therapeutic drugs, such as anti-cancer drugs and vascular disrupting agents.
- Primary indication
- Investigated for use/treatment in solid tumors.Curator reviewed
- Code names
- CYT997
Resolves to
What you can answer from here — as of October 27, 2025
Which drugs share a target with Lexibulin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account